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Polycythemia vera (PV) is a myeloproliferative disorder with relatively rare incidence. An incidence of 0.02–2.8/100,000 population per year was reported by several studies 
[1,2]. PV has no sex predilection, although the PV study group 
(PVSG) found that the disorder affects more males than females 
[3]. JAK2V617F is the most common mutation associated with a 
myeloproliferative disorder; it is a somatic mutation in the short 
arm (p) of chromosome 9. The main role of the gene is in the JAK2/
STAT pathway which signals for cell growth and proliferation. 
Other conditions associated with a mutated JAK2 gene are primary 
myelofibrosis (PMF), essential thrombocythemia (ET), Crohn’s 
disease, and Budd–Chiari syndrome. The allelic frequency of 
JAK2V617F is upward of 95% in PV, and roughly 50% in ET and 
PMF, as estimated by sensitive detection methodologies [4,5]. 
In India, the incidence of JAK2-negative PV is relatively high 
ranging up to 18% in some studies [6].
The symptoms of PV are usually secondary due to 
hyperviscosity of blood, excess histamine secretion by the cells, 
or due to splenomegaly. It is very unusual for polycythemia to 
present as hypertension; after an extensive search of the literature, 
we were able to find only one reported case of PV presenting 
as hypertension [7]. Here, we describe a case of JAK2-negative 
polycythemia presented as hypertensive urgency.
CASE REPORT
A 46-year-old male patient came to the department with a 
chief complaint of a headache for 1 day. There was no history 
of weakness of limbs, nausea, or loss of consciousness, but he 
reported numbness of both upper and lower extremities since few 
months for which he never consulted a doctor. His medical history 
and family history were negative for any significant information. 
His sleep, appetite, and bowel habits were unchanged and normal. 
He is not on any medications currently, and there is no known 
allergy. He neither smokes nor drinks alcohol.
On examination, he was conscious and oriented, with a blood 
pressure of 200/100 mmHg in the right arm in supine position, 
pulse rate of 90/min, and respiratory rate of 16/min were noted. 
No pallor, icterus, cyanosis, clubbing, lymphadenopathy, or 
edema were present. Abdominal examination revealed mild 
splenomegaly. Cardiovascular, respiratory, and nervous system 
were found to be normal on examination. A provisional diagnosis 
of a hypertensive headache was made, for which he was given 
oral antihypertensive medications and paracetamol. The blood 
pressure was moderately reduced, but headache was completely 
relieved by medication.
Laboratory investigation revealed hematocrit 0.64, 
hemoglobin 22.4 g %, white blood cell count of 9300 cells/
mcL, platelet 214,000/mcL, and RBC 6.29 million cells/mcL. 
Coagulation assays, kidney and liver function tests, and arterial 
blood gas analysis were normal. Ultrasound abdomen confirmed 
the splenomegaly. Serum erythropoietin level was 2.60. All the 
secondary causes of erythrocytosis were ruled out; other causes of 
secondary hypertension were also ruled out from history, physical 
examination, and normal serum electrolyte levels. Cytogenetic 
analysis for JAK2V617 mutation was done, which was negative 
(Fig. 1).
A diagnosis of PV was made on the basis of the British 
Committee for Standards in Haematology (BCSH) guidelines [8]. 
The criteria used for the diagnosis of PV are given in Table 1. 
Diagnosis of PV was made as A1 + A2 + A3 +A4 and B3 + B4 
are present in our case.
The patient was treated with multiple periodic phlebotomies; 
350 ml of blood removed for a total of 4 times in a month, and 
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his blood pressure came down to normal reference range and 
remained within reference range even after discontinuation of 
antihypertensive medications. His hemoglobin and hematocrit 
values also came down to a reference level.
DISCUSSION
The American College of Cardiology and American Heart 
Association (ACC/AHA) guidelines classify the blood pressure 
into various stages; Stage 1 hypertension as an average systolic 
blood pressure (SBP) of 130–139 mmHg or a diastolic blood 
pressure (DBP) of 80–89 mmHg and Stage 2 hypertension as an 
average SBP of 140 mmHg or greater or a DBP of 90 mmHg or 
greater [9]. Most cases of hypertension are primary; the incidence 
of secondary hypertension varies in different age group. In 
hypertensive adults, 5–10% is having secondary hypertension. 
The main causes of secondary hypertension are renal artery 
stenosis, aldosteronism, pheochromocytoma, obstructive sleep 
apnea, Cushing’s disease, thyroid diseases, medication-induced, 
etc. Polycythemia as a cause of secondary hypertension is 
reported rarely in literature [1].
For the diagnosis of PV, three sets of diagnostic criteria were 
described; the PVSG criteria (1975), the British Committee for 
Standards in Haematology (BCSH) criteria (1996), and the World 
Health Organization (WHO) criteria (2001). Among the three, 
the BCSH criteria are considered the most accurate with the 
acceptable level of sensitivity and ability to differentiate PV and 
other causes of erythrocytosis [10].
The mutations described recently in JAK2V617F-negative 
polycythemia are JAK2 exon12 mutation [11] and CALR 
mutations [12]. Among this, JAK2 exon12 mutation was 
associated with isolated erythrocytosis compared to the 
JAK2V617F-positive PV where there is elevated leukocyte and/or 
platelet count. The analysis of JAK2 exon12 and CALR mutations 
is not available widely. There is no significant difference in the 
presentation of JAK2-positive and negative polycythemia, but 
there is a noted significant difference in the clinical outcome of 
JAK2V617F-positive and negative PV [13,14]; JAK2-positive PV 
has a worse prognosis compared to JAK2-negative PV.
Primary familial and congenital polycythemia (PFCP) is 
a rare differential diagnosis for JAK2-negative polycythemia. 
PFCP is inherited in an autosomal dominant manner in the 
majority of cases, but some people with PFCP have no relatives 
with the disease. In about 12–15% of people with PFCP, it is 
caused by mutations in the EPOR gene [15]. However, in most 
people, the genetic cause is not yet known. Although PFCP has 
been largely reported in children and young adults, certain forms 
like the autosomal recessive Chuvashia form have been reported 
in people >40 years of age [16] but are limited to the Chuvashia 
region of Russia. Here, we excluded the PFCP since there is 
palpable splenomegaly, the absence of family history and the 
higher age of our patient.
Since the patient gives a history of witnessing a fire accident 
2 days before presentation, we have also considered the possibility 
of acute stress disorder presenting as a headache and hypertension 
in the patient, but a detailed psychiatric history and lack of other 
symptoms excluded the diagnosis.
The primary management of PV is phlebotomy combined 
with low-dose aspirin. Patients usually report an immediate 
improvement of their symptoms. Cytoreductive chemotherapy 
is recommended to control RBC volume in patients in whom 
phlebotomy is poorly tolerated, those in whom the thrombotic 
risk remains high, or those whose splenomegaly continues to be 
symptomatic. The cytoreductive agents used for the purpose are 
hydroxyurea, interferon-alpha (IFN-α), and busulfan. Ruxolitinib 
(Jakafi), a JAK1/JAK2 inhibitor, was approved by the FDA in 
December 2014 for the treatment of patients with PV who have 
had an inadequate response to or are intolerant of hydroxyurea, 
it showed a superior response compared to the best available 
treatment [17]. Splenectomy can be considered in patients with 
painful splenomegaly.
Median survival in patients PV is 1.5–3 years in the absence 
of therapy, which has been extended to approximately 14 years 
overall, and to 24 years for patients younger than 60 years of 
Table 1: Diagnostic criteria for PV
JAK2-positive PV (both criteria should to be present)
A1.  High hematocrit (>0.52 in men, >0.48 in women) or raised red 
cell mass (>25% above predicted)
A2. Mutation in JAK2
JAK2-negative PV (in the presence of A1+A2+A3+either one other A 
or two B criteria
A1.  Raised red cell mass (>25% above predicted) or hematocrit≥0.60 
in men, ≥ 0.56 in women
A2. Absence of a mutation in JAK2
A3. No case of secondary erythrocytosis
A4. Palpable splenomegaly
A5.  Presence of an acquired genetic abnormality (excluding 
BCR-ABL) in hematopoietic cells
B1. Thrombocytosis (platelet count>450×109/l)
B2.  Neutrophil leukocytosis (neutrophil count>10×109/l in 
non-smokers, and>12.5×109/l in smokers)
B3. Radiological evidence of splenomegaly
B4. Endogenous erythroid colonies or low serum erythropoietin
PV: Polycythemia vera
Figure 1: Cytogenetic analysis for JAK2V617 mutation
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age, because of new therapeutic tools [18]. The major causes 
of morbidity and mortality are thrombosis, hemorrhagic 
complications, peptic ulcer disease, myelofibrosis, and 
transformation to acute leukemia or myelodysplastic syndrome.
CONCLUSION
Even though it is a rare for polycythemia to present as 
hypertension, clinicians should consider this possibility while 
evaluating a newly diagnosed hypertension.
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